On Tuesday (January 12), researchers from Brazil have found out that China’s Sinovac vaccine that is being bought by many countries to curb COVID-19 spreads, has a low efficacy rate than announced.
During the last stage of trials in Brazil until last week, the Sinovac COVID-19 vaccine was told and was estimated by Sao Paulo researchers to have an efficacy rate of about 78%. However, this week’s data sheets have shown that patients who experienced very mild symptoms were not included in the statistics of the previous week. When the mild cases were also taken into account, the efficacy rate was brought down to just about 50.4% against mild symptoms. This means mild infections may remain.
This new finding may affect China’s health outreach. According to The New York Times, more than ten countries have already placed orders for around 380 million vaccines altogether. Malaysia and Singapore, 2 of the many countries that have placed orders, are waiting for more data to be released before they decide whether they should continue with the deal made with Sinovac. If this is the case for other countries as well, then China would fail to provide enough support and may not be able to form closer ties with other countries.
Meanwhile, Indonesia has already started its vaccination campaign with the Sinovac COVID-19 doses, with the country’s president, Mr. Joko Widodo as the first recipient of the vaccine.
Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!